BridgeBio Pharma, Inc. Common Stock insider trading
BBIOfinancial statementsForm 4 filings on EDGAR349 transactions since Nov 3, 2024
From August 6, 2026 to November 3, 2026, 0 insiders at BridgeBio Pharma, Inc. Common Stock bought $0 of stock in the open market, and 2 sold $5M. Officers and directors accounted for $0 of purchases and $5M of sales. The last reported transaction was an open-market sale by Apuli Maricel on October 30, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through November 3, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $0Sold $5MAug 6, 2026 – Nov 3, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 3, 2026. Insider data through Nov 3, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
349 transactions from November 3, 2024 to November 3, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Oct 30, 2026 | Apuli Maricel | Chief Accounting Officer | open-market sale10b5-1 | 2,000 | $72.85 | $146K | 120,687 | Nov 3, 2026 |
| Sep 17, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 8,721 | $69.01 | $602K | 496,965 | Sep 21, 2026 |
| Sep 17, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 1,279 | $69.57 | $89K | 495,686 | Sep 21, 2026 |
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 8,100 | $83.86 | $679K | 507,586 | Aug 20, 2026 |
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 1,800 | $84.69 | $152K | 505,786 | Aug 20, 2026 |
| Aug 19, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 100 | $85.65 | $9K | 505,686 | Aug 20, 2026 |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1 | 1,900 | $81.15 | $154K | 276,407 | Aug 20, 2026 |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1 | 17,279 | $82.21 | $1M | 259,128 | Aug 20, 2026 |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1 | 14,602 | $82.99 | $1M | 244,526 | Aug 20, 2026 |
| Aug 18, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1 | 1,199 | $83.77 | $100K | 243,327 | Aug 20, 2026 |
| Aug 16, 2026 | Trimarchi Thomas | President and CFO | tax withholding | 22,781 | $79.86 | $2M | 336,529 | Aug 18, 2026 |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer, Director | option exercise | 33,544 | — | — | 276,871 | Aug 18, 2026 |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer, Director | option exercise | 19,599 | — | — | 296,470 | Aug 18, 2026 |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer, Director | option exercise | 11,554 | — | — | 308,024 | Aug 18, 2026 |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer, Director | option exercise | 6,520 | — | — | 314,544 | Aug 18, 2026 |
| Aug 16, 2026 | Kumar Neil | Chief Executive Officer, Director | tax withholding | 36,237 | $79.86 | $3M | 278,307 | Aug 18, 2026 |
| Aug 16, 2026 | Apuli Maricel | Chief Accounting Officer | tax withholding | 4,714 | $79.86 | $376K | 122,687 | Aug 18, 2026 |
| Jul 30, 2026 | Apuli Maricel | Chief Accounting Officer | open-market sale10b5-1 | 2,000 | $80.06 | $160K | 127,401 | Aug 3, 2026 |
| Jul 9, 2026 | Ellis Andrea | Director | option exercise | 17,167 | $16.75 | $288K | 39,746 | Jul 13, 2026 |
| Jul 9, 2026 | Ellis Andrea | Director | open-market sale10b5-1 | 17,167 | $84.00 | $1M | 22,579 | Jul 13, 2026 |
| Jul 9, 2026 | Cook Jennifer E. | Director | option exercise | 19,000 | $8.45 | $161K | 27,383 | Jul 13, 2026 |
| Jul 9, 2026 | Cook Jennifer E. | Director | option exercise | 112,422 | $29.00 | $3M | 139,805 | Jul 13, 2026 |
| Jul 9, 2026 | Cook Jennifer E. | Director | option exercise | 17,167 | $16.75 | $288K | 156,972 | Jul 13, 2026 |
| Jul 9, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 36,167 | $84.00 | $3M | 120,805 | Jul 13, 2026 |
| Jul 9, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 112,422 | $90.00 | $10M | 8,383 | Jul 13, 2026 |
| Jun 24, 2026 | Cook Jennifer E. | Director | option exercise | 20,000 | $8.45 | $169K | 28,383 | Jun 24, 2026 |
| Jun 24, 2026 | Cook Jennifer E. | Director | option exercise | 17,167 | $16.75 | $288K | 45,550 | Jun 24, 2026 |
| Jun 24, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 37,167 | $70.00 | $3M | 8,383 | Jun 24, 2026 |
| Jun 23, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 2,196 | $68.57 | $151K | 8,383 | Jun 24, 2026 |
| Jun 23, 2026 | Valantine Hannah | Director | open-market sale10b5-1 | 2,196 | $68.57 | $151K | 9,259 | Jun 24, 2026 |
| Jun 22, 2026 | Cook Jennifer E. | Director | award | 3,990 | $0.00 | — | 10,579 | Jun 24, 2026 |
| Jun 22, 2026 | Valantine Hannah | Director | award | 3,990 | $0.00 | — | 11,455 | Jun 24, 2026 |
| Jun 22, 2026 | Valantine Hannah | Director | option exercise | 2,808 | $41.73 | $117K | 14,263 | Jun 24, 2026 |
| Jun 22, 2026 | Valantine Hannah | Director | open-market sale10b5-1 | 2,808 | $68.00 | $191K | 11,455 | Jun 24, 2026 |
| Jun 22, 2026 | Lo Andrew | Director | award | 3,990 | $0.00 | — | 18,079 | Jun 24, 2026 |
| Jun 22, 2026 | Homcy Charles J | Director | award | 3,990 | $0.00 | — | 919,876 | Jun 24, 2026 |
| Jun 22, 2026 | Aguiar Eric | Director | award | 3,990 | $0.00 | — | 10,579 | Jun 24, 2026 |
| Jun 22, 2026 | Daniels Ronald J | Director | award | 3,990 | $0.00 | — | 20,981 | Jun 24, 2026 |
| Jun 22, 2026 | Ellis Andrea | Director | award | 3,990 | $0.00 | — | 22,579 | Jun 24, 2026 |
| Jun 22, 2026 | Hassan Fred | Director | award | 3,990 | $0.00 | — | 29,879 | Jun 24, 2026 |
| Jun 22, 2026 | Momtazee James C | Director | award | 3,990 | $0.00 | — | 19,070 | Jun 24, 2026 |
| Jun 22, 2026 | Mccormick Frank | Director | award | 3,990 | $0.00 | — | 10,579 | Jun 24, 2026 |
| Jun 22, 2026 | Dachille Douglas A. | Director | award | 3,990 | $0.00 | — | 10,579 | Jun 24, 2026 |
| Jun 22, 2026 | Satvat Ali J. | Director | award | 3,990 | $0.00 | — | 169,983 | Jun 24, 2026 |
| Jun 20, 2026 | Homcy Charles J | Director | tax withholding | 788 | $66.27 | $52K | 915,886 | Jun 23, 2026 |
| Jun 15, 2026 | Cook Jennifer E. | Director | option exercise | 65,921 | $8.45 | $557K | 79,662 | Jun 17, 2026 |
| Jun 15, 2026 | Cook Jennifer E. | Director | option exercise | 17,167 | $16.75 | $288K | 96,829 | Jun 17, 2026 |
| Jun 15, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 88,737 | $66.62 | $6M | 8,092 | Jun 17, 2026 |
| Jun 15, 2026 | Cook Jennifer E. | Director | open-market sale10b5-1 | 1,503 | $67.14 | $101K | 6,589 | Jun 17, 2026 |
| Jun 5, 2026 | Kumar Neil | Chief Executive Officer, Director | open-market sale10b5-1indirect | 7,147 | $67.20 | $480K | 528,539 | Jun 8, 2026 |
Who the insiders are
Everyone who reported a transaction since November 3, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer, Director | Sep 17, 2026 | open-market sale | 276,407 | — | $57M (114) | 114 of 114 |
| Cook Jennifer E. | Director | Jul 9, 2026 | option exercise | 27,383 | — | $22M (6) | 6 of 6 |
| Lo Andrew | Director | Jun 22, 2026 | award | 18,079 | — | $6M (4) | 0 of 4 |
| Ellis Andrea | Director | Jul 9, 2026 | option exercise | 39,746 | — | $6M (2) | 2 of 2 |
| Valantine Hannah | Director | Jun 23, 2026 | open-market sale | 9,259 | — | $4M (6) | 5 of 6 |
| Daniels Ronald J | Director | Jun 22, 2026 | award | 20,981 | — | $4M (1) | 0 of 1 |
| Trimarchi Thomas | President and CFO | Aug 16, 2026 | tax withholding | 336,529 | — | $3M (6) | 6 of 6 |
| Scott Randal W. | Director | May 15, 2026 | option exercise | 21,589 | — | $2M (9) | 9 of 9 |
| Apuli Maricel | Chief Accounting Officer | Oct 30, 2026 | open-market sale | 120,687 | — | $767K (6) | 6 of 6 |
| Mccormick Frank | Director | Jun 22, 2026 | award | 10,579 | — | — | — |
| Stephenson Brian C | CFO and Treasurer | Feb 25, 2025 | open-market sale | 102,564 | — | — | — |
| Homcy Charles J | Director | Jun 22, 2026 | award | 919,876 | — | — | — |
| Satvat Ali J. | Director | Jun 22, 2026 | award | 169,983 | — | — | — |
| Aguiar Eric | Director | Jun 22, 2026 | award | 10,579 | — | — | — |
| Hassan Fred | Director | Jun 22, 2026 | award | 29,879 | — | — | — |
| Momtazee James C | Director | Jun 22, 2026 | award | 19,070 | — | — | — |
| Dachille Douglas A. | Director | Jun 22, 2026 | award | 10,579 | — | — | — |
| Halvorsen Ole Andreas | 10% owner | Jun 27, 2025 | open-market sale | — | — | — | — |
| Kravis Henry R | 10% owner | May 12, 2025 | open-market sale | — | — | — | — |
| KKR Group Holdings Corp. | 10% owner | Mar 5, 2025 | open-market sale | — | — | — | — |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10% owner | Jan 31, 2025 | open-market sale | — | — | — | — |
Questions
Are BridgeBio Pharma, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 3, 2026, 9 insiders at BridgeBio Pharma, Inc. Common Stock sold $105M of stock in the open market, all by officers and directors, and no insider bought. Net, insiders sold $105M. Only open-market purchases and sales are counted.
Who sold the most BridgeBio Pharma, Inc. Common Stock stock in the last year?
Kumar Neil (Chief Executive Officer, Director) sold $57M in 114 open-market sales over the twelve months to November 3, 2026.
Do BridgeBio Pharma, Inc. Common Stock executives sell under 10b5-1 plans?
148 of the 154 open-market sales in the last twelve months (96%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on BridgeBio Pharma, Inc. Common Stock
- BridgeBio Pharma, Inc. Common Stock financial statements
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.